Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The primary myelofibrosis market size was valued at USD 877.43 million in 2023, driven by the increasing prevalence of myelofibrosis across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 to achieve a value of USD 1438.9 million by 2032.
Myelofibrosis is a rare blood cancer where scar tissue forms in your bone marrow. It is a type of chronic leukemia that involves too many abnormal blood cells being made. Eventually, these cells can replace normal cells. Treatment goals mainly involve managing symptoms and conditions that arise, including anemia and an enlarged spleen. Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.
The market growth is driven by the increased prevalence of primary myelofibrosis. The key market players are increasing their efforts toward discovering and producing the best and most effective treatment options to increase life expectancy worldwide. The recent developments in the field of myelofibrosis have been exhibited by the FDA approval of Ojjaara (momelotinib) by GSK plc and the Fast Track Designation granted to selinexor by Karyopharm Therapeutics Inc., are anticipated to have a significant positive impact on the growth of the primary myelofibrosis market.
People with myelofibrosis often develop anemia, which is a problem resulting in more than 30% of patients discontinuing the treatment. Recently, the FDA has approved a new medicine called Ojjaara. This once-a-day pill targets JAK1, JAK2, and ACVR1. This medicine has exclusively been made for those with intermediate or high-risk myelofibrosis, including both primary and secondary types. By effectively targeting key disease manifestations such as anemia, constitutional symptoms, and splenomegaly, Ojjaara is poised to offer a comprehensive therapeutic solution and boost the primary myelofibrosis market growth.
Furthermore, the Fast Track Designation granted to selinexor exemplifies the industry's commitment to advancing innovative therapies for myelofibrosis patients, reflecting a proactive approach to expedite the development of potential treatments. As ongoing clinical trials explore various therapeutic options, the forecast period is expected to witness a surge in FDA-approved treatments for myelofibrosis, thereby propelling the growth of the primary myelofibrosis market. This increase in approved treatments not only expands the spectrum of available therapeutic interventions but also addresses the unmet needs of patients, contributing to the overall advancement of myelofibrosis care.
Market Breakup by Type
Market Breakup by Services
Market Breakup by Dosage Forms
Market Breakup by Age
Market Breakup by End User
Market Breakup by Region
The increasing emphasis on research and development activities by key players is expected to potentially create lucrative opportunities for primary myelofibrosis treatment market growth. Primary myelofibrosis is a rare disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The incidence rate of myelofibrosis ranged from 0.1 to 1 case per 100,000 per year. The additional market growth can be attributed to the increasing awareness regarding Primary Myelofibrosis (PMF) treatment and the rise in the number of patients is also poised to result in increased production of more effective and targeted treatment drugs and JAK inhibitors.
The healthcare sector has been improving, and favorable government initiatives, reimbursement policies, and changing dietary patterns are collectively contributing to the primary myelofibrosis market growth. These factors, along with the busy lifestyle, are contributing to the growth of the market. Additionally, the market is expected to grow further due to increased investments in research and development activities aimed at developing precise treatments for myelofibrosis in the forecast period.
Geographically, North America is currently dominating the regional market and is expected to drive market growth in the forecast period as well. The market growth is expected to be driven by the increased research and development activities by key players in order to develop more effective and targeted treatment options for the patients, resulting in better patient outcomes. Also, the presence of some of the key players in the region is also propelling the market growth.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Services |
|
Breakup by Dosage Forms |
|
Breakup by Age |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 877.43 million in 2023, driven by the increased prevalence of the condition.
The market is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 1438.9 million by 2032.
The approval of newly developed targeted drugs to treat primary myelofibrosis is driving the market growth.
The clinical development and continuous efforts of scientists to discover new JAK inhibitors to find better treatments for primary myelofibrosis are major trends influencing the market growth.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain) and United Kingdom.
Different types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, and episodic primary myelofibrosis, among others.
The services can be categorised into treatment and diagnosis.
The dosage forms include solid and liquid, among others.
The condition can affect condition can affect people from children to adults to geriatric.
The end-users can be divided into hospitals and clinics, among others.
Key players involved in the market are Bristol-Myers Squibb Company, Amneal Pharmaceuticals, Inc., CTI BioPharma Corp, Actuate Therapeutics Inc., Pfizer Inc., Galecto, Incyte Corporation, AbbVie Inc., GlaxoSmithKline plc, Imago BioSciences, Sanofi, F. Hoffmann-La Roche Ltd, Mylan NV, Hikma Pharmaceuticals PLC, and Bayer AG.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share